Compare NSP & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NSP | GPCR |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1997 | 2023 |
| Metric | NSP | GPCR |
|---|---|---|
| Price | $38.86 | $68.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $47.67 | ★ $97.90 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 02-09-2026 | 11-06-2025 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $6,757,000,000.00 | N/A |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $6.40 | N/A |
| P/E Ratio | $87.11 | ★ N/A |
| Revenue Growth | ★ 3.19 | N/A |
| 52 Week Low | $31.00 | $13.22 |
| 52 Week High | $95.98 | $94.90 |
| Indicator | NSP | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 67.64 |
| Support Level | $37.99 | $66.58 |
| Resistance Level | $39.50 | $72.00 |
| Average True Range (ATR) | 1.17 | 3.84 |
| MACD | 0.20 | -0.34 |
| Stochastic Oscillator | 69.25 | 75.13 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.